Paper
0
Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial
Authors
Marc Raab,Niels Weinhold
K. Kortüm,Jan Krönke,Lilli Podola,Uta Bertsch,Jan Frenking,Julia Mersi,Stefanie Huhn,Michael Hundemer,Gunhild Mechtersheimer,Roland Fenk,Katja Weisel,Natalie Schub,Florian Bassermann,Monika Engelhardt,Raphael Teipel,Mathias Hänel,Hans Salwender,Bas Koster,Elena Ershova,Caline Sakabedoyan,Isobel Barrott,Ágnes Balogh,Sanjay Vara,Tobias Kampfenkel,Hartmut Goldschmidt,Hermann Einsele,Leo Rasche
+27 authors
,U. BertschJournal
Published
Nov 5, 2024
Show more
Save
Tip0
TipSave
Abstract
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.